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Abstract
The survival of patients affected by cutaneous melanoma has improved dramatically in the last 10 years, because of earlier
diagnosis. Despite this, the therapeutic results obtained in metastatic melanoma (MM) are very disappointing due to its poor
responsiveness to cytotoxic agents. In this type of solid tumor, tumor chemosensitivity assays have been suggested to be an
important tool to predict clinical responsiveness to therapy. Metastatic melanoma cells (MMCs) were obtained from subcu-
taneous melanoma metastases of five patients and cultured for several consecutive passages. An immunofluorescence and an
electron microscopic study were performed in order to establish the ultrastructural and physiopathological features of MMCs. A
sulphorodamine-B test was used to measure in vitro sensitivity of MMCs to temozolomide, cisplatin, vindesine, taxol and
interpheron alpha-2a. Following a 72 h exposure, maximum activity was obtained with vindesine (median inhibitory concen-
tration, IC50, 0.23 nM) and taxol (median IC50 0.31 nM). Cisplatin median IC50 values were higher (4.6 mM) than taxol and
vindesine, but still in the range of clinically achievable plasma concentrations. Temozolomide inhibited cell proliferation only
at very high concentrations (median IC50 228 mM). No significant cell growth inhibitory effects (#25%) were observed with
interferon alpha-2a concentrations up to 8000 IU/ml. MMCs expressed progression markers typical of cutaneous metastatic
melanoma and showed poor sensitivity in vitro to most anticancer drugs tested, including temozolomide. q 2002 Elsevier
Science Ireland Ltd. All rights reserved.
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1. Introduction
The survival of patients with cutaneous melanoma
has improved dramatically in the last 10 years, espe-
cially due to the increasingly earlier diagnosis [1].
Metastatic melanoma (MM), conversely, represents
a very difficult challenge for medical oncologists
having a median survival of only 7 months and an
overall 5-year survival ,10% [2,3], despite the
several immunochemotherapy approaches attempted.
These poor results are due to the particularly low
chemosensitivity of MM.
The basic defects which underlie chemoresistance
in human solid tumors are related to altered expres-
sion of specific drug resistance genes [4] or of onco-
genes (e.g. p53, bcl2) [5–7] also involved in the
development of generalized drug resistance. For
instance, the development of resistance to temozolo-
mide in melanoma cells is often accompanied by an
increase in O6-methylguanine-DNA methyltransfer-
ase activity and by reduction of DNA mismatch repair
proteins [8], the latter also being a main mechanism
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involved in resistance to platinum compounds [9].
The acquisition of an altered oncogenic phenotype
(e.g. mutated p53, loss of p16 gene expression)
which occurs frequently in primary cutaneous mela-
noma [10–12] may also be the basis for melanoma
cells to become resistant to cytotoxic drugs.
According to many reported clinical trials, the
chemosensitivity of MM to currently used drugs is
heterogeneous [13]. This offers a possible explanation
for the observed clinical response, often unpredictable
and overall poor. Chemosensitivity assays have been
recently proposed as an important tool to predict
tumor responsiveness to clinical treatment [14–16].
In this study, the cytotoxicity of the drugs usually
used in the clinical treatment of MM was assessed in
vitro by a sulphorodamine-B colorimetric assay [17]
against metastatic melanoma cells (MMCs) from
patients. MMCs isolated from subcutaneous mela-
noma metastases and cultured for several consecutive
passages, were also studied in immunofluorescence
and at electron microscopy.
2. Material and methods
2.1. Patient characteristics
Cutaneous melanoma metastases were taken from
five patients whose major clinical patterns are
summarized in Table 1. Three patients had not
received previous drug treatment (nos. 1, 2 and 4),
while two patients (nos. 3 and 5) were administered
interferon alpha-2a (10 millions s.c. three times
weekly). Following biopsy, all five patients received
medical treatment for their advanced disease. Patient
no. 1 received two courses of temozolomide, (250 mg/
m2 i.v. daily for 5 consecutive days every 1 month)
but progressed and died after 4 months due to distant
metastases. Patient no. 2 was given interferon alpha-
2a (10 millions s.c. three times weekly) and this treat-
ment is still ongoing 16 months later. The patient is
still experiencing a partial response. The brain metas-
tasis of this last patient was treated with standard
whole brain radiotherapy.
Patient no. 3 received combined chemotherapy
(one course of the CVD regimen, i.e. a combination
of cisplatin, vindesine, dacarbazine) but died due to
disease progression after 1.5 months. Patient no. 4
underwent six courses of dacarbazine treatment,
experiencing stable disease, thereafter new metastases
in transit appeared and interferon alpha-2a was admi-
nistered (for 3 more months) but disease progressed
and the patient died 8 months after therapy stop.
Patient no. 5 was given a combination of dacarbazine
and interferon alpha-2a for 8 months (disease stabili-
zation was obtained) and then two courses of CVD,
but he died 3 months after the latter treatment.
2.2. Melanoma specimens and cell culture
The metastatic skin samples were taken from
subcutaneous metastases of five melanoma patients.
Each skin metastasis was deprived of fat, washed
many times in phosphate buffered saline (PBS) and
antibiotics and cut into many tiny pieces. The first
enzymatic digestion was performed with protease
(Boeheringer/Mannheim, Mannheim, Germany) for
4 h at 378C in RPMI 1640 medium (Calbiochem,
Parmstad, Germany) with 1% penicillin/streptomycin
(Sigma-Aldrich, Milan, Italy). The medium with the
cells was then centrifuged and the supernatant was
discarded. A second enzymatic digestion was then
performed with collagenase (Sigma) for 3 h at
378C in 5% CO2 humidified atmosphere. The enzy-
matic action was stopped with a combination of Tris
Base, NaCl and EDTA. The cells were then put in
RPMI 1640 medium with 10% fetal calf serum (FCS)
(Sigma), 5% penicillin/streptomycin (Sigma) and 5%
glutamine (Sigma) and cultured for numerous conse-
cutive passages (at least 20 passages for each
patient).
2.3. Assessment of immunophenotype
MMCs were grown on chamber slides (Nunc Inter-
national, Roskilde, Denmark), were rehydrated,
blocked with 5% FCS, and incubated with primary
monoclonal antibodies against S-100 (Sigma),
HMB-45 (Dako, Milan, Italy), granulocyte-macro-
phage colony-stimulating factor (GM-CSF) (Sera
Lab, Heidelberg, Germany), c-kit (Novo Castra,
Segrate, Milan, Italy). This incubation was protracted
for 90 min at 378C and was followed by a fluorescein-
isothiocyanate-conjugated goat anti-mouse antibody
(Sigma). The slides were mounted with Gel/Mount
(Biomeda, Augst, Switzerland) for 1 h at 378C and
observed under a Zeiss Axioskop microscope
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Table 1
Clinical and immunophenotypic characteristics of the patientsa
Patient no. Age/sex Stage Metastatic site (s) Pre-treatment Post-treatment Resp Survival (months) S-100 HMB-45 GM-CSF c-kit
1 34/M IV Skin None Temozolomide P 4 1 1 2 2
Surrenal gland
Brain
2 70/F III-B Skin None IFN-a2a PR 161 1 1 2 1
Brain
3 51/M IV Lung IFN-a2a CVD regimen P 1.5 1 1 1 1
Lymphonodes
(multiple sites)
4 72/M III-B Skin None 1 DTIC S 17 1 1 1 2
Liver
Lymphonodes 2 IFN-a2a P
Brain
5 79/M IV Skin IFN-a2a 1 DTIC1 IFN-a2a S 13 1 1 1
Lung
Lymphonodes 2 CVD regimen P
a CVD, cisplatin, vindesine and dacarbazine; P, progression; PR, partial response; and S, stable disease.
equipped for epifluorescence. The working dilutions
for the monoclonal antibodies were the following:
prediluted for S-100, 1:30 for HMB-45, 1:60 for
GM-CSF, 1:200 for c-kit.
2.4. Morphology
For electron microscopy analysis, samples were
collected at the very beginning of all cultures, after
five passage and after ten passages in vitro. This
procedure has already been standardized in our
laboratory [18]. At each time point, MMCs grown in
Petri culture dishes (Costar, Cambridge, MA) were
washed with PBS, trypsinized and then fixed with a
mixture of 2% formaldehyde and 2.5% glutaralde-
hyde in 0.1 mmol/l cacodylate buffer, pH 7.4, at
room temperature for 10 min; the MMCs were then
osmicated and embedded in Epon. Ultrathin sections
were stained with uranyl acetate followed by bismuth
tartrate and lead citrate and observed in a Siemens 102
electron microscope, at 80 kV.
2.5. Drugs
Temozolomide, cisplatin, vindesine, taxol and
interferon alpha-2a were obtained from commercial
sources. Stock solutions of temozolomide were
prepared in RPMI 1640. Stock solution of temozolo-
mide was freshly prepared in dimethylsulphoxide
(0.66% in RPMI); serial dilutions of all the drugs
for incubation were prepared in RPMI 1640 complete
medium.
2.6. Cell growth inhibition studies
MMCs were seeded in 96-well microplates at a
cell density of 5 £ 103 cells/ml and allowed to
grow for 24 h before treatment. In vitro cytotoxic
single agent activity was evaluated following incuba-
tion of cells for 72 h to: temozolomide (5 £ 1028–
5 £ 1024 M), cisplatin (1 £ 1028–5 £ 1025 M), vinde-
sine (5 £ 10213–5 £ 1029 M), taxol (5 £ 10211–
5 £ 1027 M) and interferon alpha-2a (125–8000 IU/
ml). The drug concentrations tested were in the range
of those achievable in the plasma following admin-
istration of the usual therapeutic drug doses [19–23].
At the end of treatment cells were fixed with trichlor-
oacetic acid (50% aqueous solution) at 48C for 1 h,
air-dried and stained for 30 min with sulphorodamine
B (SRB) 0.4% in 1% acetic acid at room tempera-
ture. Then SRB was removed and protein-bound dye
was extracted with 10 mM unbuffered Tris base (pH
10) for 15 min in a gyratory shaker. The optical
density was read in a computer-interfaced, 96-well
microtiter plate reader at 540 nm (Model Benchmark,
Biorad).
Chemosensitivity of MMCs was expressed as IC50
corresponding to the concentration of drug producing
a 50% inhibition of cell proliferation as compared to
untreated cell control.
2.7. Statistical analysis
Cell growth inhibitory effects produced by the
different drugs on MMCs were analyzed by Student’s
t-test.
3. Results
3.1. Ultrastructure data
All MMCs expressed the S-100 (Fig. 1a and Table
1) and HMB-45 antigens (Fig. 1b and Table 1) which
are both melanocyte markers; MMCs obtained from
three patients were GM-CSF positive (Fig. 1d and
Table 1); MMCs obtained from one patient were c-
kit positive (Fig. 1c and Table 1); MMCs from the
fourth patient were GM-CSF and c-kit positive and
MMC of the fifth patient expressed neither GM-CSF
nor c-kit. This phenotype was evaluated at each
passage in vitro for S-100 and HMB-45, and at each
third passage for the antigens GM-CSF and c-kit. The
MMCs were cultured for 20 passages and the immu-
nophenotype was always the same.
While the expression of c-kit by MMCs is indica-
tive of a biological influence by stem cell factor (SCF)
on MMCs and is variously expressed by MMCs, GM-
CSF is always up-regulated in late melanoma metas-
tases. By electron microscopy, MMCs showed the
typical morphology of well differentiated melano-
cytes, which were characterized by dendritic
morphology, were rich in organelles such as mito-
chondria, smooth and rough endoplasmic reticulum
and Golgi apparatus (Fig. 2) and, above all, there
were melanosomes in different stages of maturation
in their cytoplasm (Fig. 3). The cells connected to
each other without specialized junctions such as
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desmosomes. All the cells showed no signs of apop-
tosis, neither at cytoplasmic and nuclear membranes
nor at organelles, as shown in all figures.
3.2. Effects of drugs on cell growth
Concentration-response curves and IC50 values
concerning in vitro cytotoxicity tests are reported in
Fig. 4 and Table 2. The most in vitro active drugs were
taxol and vindesine, with IC50 values ranging from
0.079 to 0.4 nM and from 0.12 to 0.27 nM, respec-
tively, in the five cases tested (median IC50 values 0.31
and 0.23 nM, respectively).
MMCs were less sensitive to cisplatin with IC50
values ranging from 3.3 and 4.7 mM (median value
3.8 mM). In all five cases temozolomide IC50 values
higher than 200 mM have been obtained (median
value 228 mM). No significant inhibitory effects on
cell growth ($25%) were noted using interferon
alpha-2a concentrations up to 8000 IU/ml.
Thus the in vitro potency of the drugs tested could
be graded as follows: vindesine ¼ taxol.
cisplatin. temozolomide. interferon alpha-2a. The
differences in cytotoxicity observed among the differ-
ent drugs were statistically significant (P , 0:05).
Interestingly, the drug sensitivity patterns of MMCs
did not vary in relationship to expression of tumor
progression markers tested (GM-CSF, c-kit).
Despite the limited number of cases a correlation
between in vitro cytotoxicity data and clinical response
of patients treated with chemotherapy was attempted.
Disparate clinical results were obtained in patients who
were administered interferon alpha-2a after biopsy (i.e.
a partial response in patient no. 2, progression in
patient no. 4 who received single agent interferon
alpha-2a as first-and second-line treatment for their
metastatic disease, respectively; stable disease in
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Fig. 1. Indirect immunofluorescence: MMCs in culture, expression of melanocyte immunophenotypical markers: (a) S-100; (b) HMB-45; (c)
cells positive to c-kit; and (d) to GM-CSF. (Magnification: £ 200).
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Fig. 3. Electron microscopy: melanosomes in various degree of differentiation were present in the cytoplasm of MMCs. (Magnification:
£ 75 000).
Fig. 2. Electron microscopy: a melanocyte characterized by dendritic morphology; its cytoplasm appeared rich in organelles, especially
mitochondria, smooth and rough endoplasmic reticulum and Golgi apparatus. (Magnification: £ 15 000).
patient no. 5 who was treated with a combination of
interferon alpha-2a and dacarbazine after tumor
biopsy).
Following temozolomide or dacarbazine treatment
clinical responses also varied. In two cases (patients
nos. 4 and 5) first-line treatment with dacarbazine
alone or dacarbazine plus interferon-alpha-2a
induced disease stabilization, while in two other
cases (patients nos. 3 and 5) a dacarbazine based
regimen (CVD) did not hamper disease progression.
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Fig. 4. Effect of drugs on metastatic melanoma cell growth. Cells were exposed to drugs for 72 h. Each value represents the mean of eight wells
of a representative experiment repeated at least twice.
Temozolomide was used in only one patient (patient
no. 1) but failed to control disease progression. The
clinical use of cisplatin and vindesine was limited, in
our case series, to two patients, within the CVD
regimen, (patients nos. 3 and 5) and was unsuccess-
ful. None of the patients received taxol therapy.
Agreement between in vitro drug sensitivity/resis-
tance data and clinical response to the seven treat-
ments performed was present in only two cases
while discrepancies were observed in the other five
cases.
4. Discussion
The immunophenotypical and ultrastructural data
proved that all the cell cultures obtained with this
isolation tecnique were melanocytes. All five cell
cultures expressed the antigens S-100 and HM-B45,
immunophenotypical markers of melanocytes [24].
Melanocytes obtained from two patients were c-kit
positive; c-kit is the natural ligand of SCF, a cytokine
which controls human melanocyte homeostasis,
promoting hyperplasia and functional activation on
melanocytes in vivo [25] and growth inhibitory effects
on c-kit expressing melanoma cells [26]; a downregu-
lation of c-kit has been reported in the later stages of
melanoma that might permit escape from c-kit growth
control [27] or allow melanoma cells to evade immu-
nosurveillance by reducing the expression of differen-
tiation antigens [28].
Three MMCs were positive for GM-CSF. The
expression of this cytokine and other growth factors
is correlated with tumor progression and is usually
increased in later stages of melanoma [29,30].
The ultrastructural data proved that all the cells were
well differentiated melanocytes as shown by the
presence of smooth and rough endoplasmic reticulum,
Golgi apparatus, the richness in mitochondria and
above all by the presence of many melanine granules
in various stages of maturation within the cytoplasm of
MMCs. None of the melanocytes was in apoptosis, as
demonstrated by the integrity of cytoplasmic and
nuclear membranes, as well as that of mitochondria
and by the total absence of apoptotic bodies.
In regard to the chemosensitivity assay data, the
concentration-response curves for each single drug
were similar in all cell cultures tested. Although a
slight variability in cytotoxic effects was observed at
low drug concentrations for each single melanoma
cell culture, the IC50 values were in fact very similar.
Differences in in vitro cytotoxicity induced by the
different drugs used were however remarkable. The in
vitro cyotoxic activity of taxol and vindesine was very
high (IC50 values in the nanomolar range), mainly
below the peak concentrations obtainable in the
plasma with clinical administration of these drugs
[23,19].
Considerable in vitro cytotoxic effects were also
obtained with cisplatin at median IC50 in the range
of clinically achievable plasma concentrations [22].
On the contrary a high degree of in vitro resistance to
temozolomide and interferon alpha-2a was observed.
In our experience disparate clinical results were
obtained in patients receiving interferon alpha-2a
after biopsy, with poor correlation to in vitro results.
To explain the lack of in vitro activity by interferon
alpha-2a, it should be remembered that this drug has
only minor direct cytotoxic effects on MMCs but
possesses diverse immunomodulatory effects on
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Table 2
Cytotoxicity data following continuous drug exposure (72 h) of metastatic melanoma cell culturesa
Drugs IC50 (mM) Patient no.
1 2 3 4 5 Median
Temozolomide 228 227.5 245 220 246.5 228
Cisplatin 3.0 ^ 0.5 3.3 ^ 0.4 3.8 4.6 4.7 3.8
Vindesine 0.00012 0.00027 0.00027 0.00023 0.00021 0.00023
Taxol 0.00034 ^ 0.0001 0.000079 ^ 0.00001 0.00031 0.00026 0.0004 0.00031
Interferon-a-2a (UI) .8000 .8000 .8000 .8000 .8000 nd
a Data are reported as IC50 (mM) values expressed as mean ^ SE of at least three determinations or mean of two determinations.
tumoral cells which cannot be fully reproduced in
vitro. In particular, interferon is much more effective
on cells of the microenviroment than on MMCs
[31,32]; its antiproliferative and immunomediated
effects are obtained through enhanced natural-killer
cell activity or upregulation of tumor antigens and/or
human leukocyte antigen classes I and II antigens [32].
Temozolomide is a novel oral alkylating agent
which, at variance with dacarbazine, does not need
hepatic cytochrome p450-mediated metabolic activa-
tion to generate an active drug such as imidazole-4-
carboxamide [20]. It is thus an important tool for
detecting possible in vitro activity of triazenes.
While the efficacy of temozolomide in metastatic
melanoma has been widely demonstrated in clinical
trials [33], high levels of in vitro resistance were
observed in our case series. Raymond and coworkers
[34] reported, however, 33% in vitro activity of temo-
zolomide in melanomas as detected by a soft agar
tumor cloning system.
The clinical use of cisplatin and vindesine (within
the CVD regimen) was unsuccessful, leading to
disease progression. Also these results are at odds
with the in vitro chemosensitivity data that showed
generalized activity of cisplatin (of moderate degree)
and of vindesine (of very high degree).
Our data arise from a limited case-series and it is
not possible to draw a clear-cut conclusion about the
in vitro-studies and the clinicopathological relation-
ship; further research on a more extended number of
observations will be necessary. They raise, however,
some doubts about the possible clinical predictability
of in vitro tumor chemosensitivity assay-results for
cutaneous metastatic melanoma. The tecnique that
we have used (sulphorodamine B assay) appears to
be sensitive and accurate for detecting cytotoxic
drug effects in long term primary cultures of
MMCs. Other techniques such as those based on
soft agar cloning [35] or measurement of intracellu-
lar adenosine-5 0-triphosphate content by chemolumi-
nescence [16,36–37] have obtained positive
correlation between in vitro sensitivity data and clin-
ical responsiveness, allowing speculation about the
use of tumor chemosensitivity assays to tailor patient
therapy. Our results appear to suggest caution in
promoting assay-directed chemotherapy for cuta-
neous melanoma patients, as pointed out also by
other authors [38].
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